The table below shows Ultragenyx Pharmaceutical Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$197.00M
-$166.00M
-$190.73M
-$156.87M
-$117.52M
-$159.35M
Capital expenditure
$1.00M
$1.00M
$3.21M
$25.03M
$32.18M
$16.41M
Investing cash flow
-$49.00M
$120.00M
$94.44M
$111.30M
-$37.36M
-$182.42M
Dividends paid
-
-
-
-
RARE operating cash flow (10-K history)
Ultragenyx Pharmaceutical Inc. reported operating cash flow of -$466.00M for fiscal year 2025. That is down 12.6% from -$414.00M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$160.97M (FY 2016) to -$466.00M. Figures come from the company's audited annual reports as filed with the SEC.